Friday, August 17, 2018 9:38:00 AM
(from) European Commission’s Horizon 2020 research and innovation plan:
Alongside the Cell and Gene Therapy Catapult, the founding partners of the RESTORE consortium comprise world leaders across academia, clinical research and industry, including Charité Universitätsmedizin Berlin (Germany), INSERM – Institut National de la Santé et de la Recherche (France), University of Zurich (Switzerland), Miltenyi Biotec GmbH (Germany), TissUse GmbH (Germany), Pluristem Ltd (Israel), Fondazione Telethon (Italy), University Minho (Portugal) and Innovation Acta S.r.l. (Italy).
Clearly, Pluristem is part of the most important avant-garde in the most important new medical paradigm, i.e. harnessing the power of stem cells as therapeutic agents. Note that the article includes Pluristem in a very exclusive club: world leaders across academia, clinical research and industry
Thanks for the link Allo!
PS: I just noticed that the same paragraph was already excerpted by Allo in the next post, but I'll leave this anyway, I think it's very important to appreciate the arena Pluristem is playing in!
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM